3.06
10.26%
-0.35
Opgen Inc stock is currently priced at $3.06, with a 24-hour trading volume of 73,489.
It has seen a -10.26% decreased in the last 24 hours and a +659.31% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.44 pivot point. If it approaches the $3.11 support level, significant changes may occur.
Previous Close:
$3.41
Open:
$3.38
24h Volume:
73,489
Market Cap:
$3.86M
Revenue:
$3.07M
Net Income/Loss:
$-26.16M
P/E Ratio:
-0.2539
EPS:
-12.05
Net Cash Flow:
$-17.84M
1W Performance:
-7.27%
1M Performance:
+659.31%
6M Performance:
+637.70%
1Y Performance:
+307.13%
Opgen Inc Stock (OPGN) Company Profile
Name
Opgen Inc
Sector
Industry
Phone
240 813 1260
Address
9717 Key West Avenue, Suite 100, Rockville, MD
Opgen Inc Stock (OPGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-01-19 | Initiated | Alliance Global Partners | Buy |
Feb-07-18 | Reiterated | H.C. Wainwright | Buy |
Jun-29-16 | Initiated | Rodman & Renshaw | Buy |
Opgen Inc Stock (OPGN) Latest News
Q2 2023 OpGen Inc Earnings Call - Yahoo Canada Sports
Yahoo Canada Sports
Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar ... - Yahoo Movies Canada
Yahoo Movies Canada
Ratios Reveal: Breaking Down Opgen Inc (OPGN)'s Financial Health – DWinneX - The Dwinnex
The Dwinnex
OpGen Receives Expected Nasdaq Notice Regarding Delayed - Head Topics
Head Topics
OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Defense World
OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - OpGen, Inc.
OpGen, Inc.
Opgen Inc Stock (OPGN) Financials Data
Opgen Inc (OPGN) Revenue 2024
OPGN reported a revenue (TTM) of $3.07 million for the quarter ending September 30, 2023, a -7.28% decline year-over-year.
Opgen Inc (OPGN) Net Income 2024
OPGN net income (TTM) was -$26.16 million for the quarter ending September 30, 2023, a +22.04% increase year-over-year.
Opgen Inc (OPGN) Cash Flow 2024
OPGN recorded a free cash flow (TTM) of -$17.84 million for the quarter ending September 30, 2023, a +13.34% increase year-over-year.
Opgen Inc (OPGN) Earnings per Share 2024
OPGN earnings per share (TTM) was -$6.51 for the quarter ending September 30, 2023, a +64.54% growth year-over-year.
About Opgen Inc
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):